Pipeline Promise | Explore Kodiaq Sciences' diverse eye disease treatment portfolio, including KSI-101, tarcocimab, and KSI-501, with key trial results expected in 2025-2026 |
Financial Hurdles | Delve into the company's financial challenges, with negative EPS forecasts and a declining stock price, balanced against its cash-rich balance sheet |
Market Positioning | Learn how Kodiaq Sciences aims to differentiate itself in the competitive biotech sector through innovative treatments and a new wearable OCT device |
Future Outlook | Analyst price targets range from $3 to $4, reflecting cautious optimism amid clinical trial uncertainties and potential market opportunities |
Metrics to compare | KOD | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipKODPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.3x | −3.1x | −0.5x | |
PEG Ratio | 0.49 | 0.11 | 0.00 | |
Price/Book | 57.7x | 5.3x | 2.6x | |
Price / LTM Sales | - | 55.7x | 3.3x | |
Upside (Analyst Target) | 74.4% | 178.8% | 47.0% | |
Fair Value Upside | Unlock | −0.9% | 5.9% | Unlock |